Drug interactions
Finerenone + Liposomal doxorubicin
Severity: Minor
Finerenone and Liposomal doxorubicin: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Doxorubicin is not an established CYP3A4 inhibitor, so a meaningful rise in finerenone exposure is unlikely. Finerenone can raise serum potassium, and patients receiving chemotherapy may have vomiting, dehydration or renal impairment that increase the risk of hyperkalemia.
What this interaction means in plain words
Finerenone and Liposomal doxorubicin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Finerenone belongs to Cardiovascular; Liposomal doxorubicin belongs to Oncology.
Why it happens
Any CYP3A4 inhibition by doxorubicin is not clinically established; the main concern is finerenone-related hyperkalemia.
What to do
Monitor serum potassium and renal function during chemotherapy cycles. Adjust the finerenone dose if potassium rises.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Finerenone and Liposomal doxorubicin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Liposomal doxorubicin
- Dengue vaccine + Liposomal doxorubicin Contraindicated
- Belatacept + Liposomal doxorubicin Major
- Cyclosporine + Liposomal doxorubicin Major
- Dronedarone + Liposomal doxorubicin Major
- Elvitegravir / cobicistat / emtricitabine / tenofovir df + Liposomal doxorubicin Major
- Fingolimod + Liposomal doxorubicin Major
Other interactions of Finerenone
- Carbamazepine + Finerenone Contraindicated
- Clarithromycin + Finerenone Contraindicated
- Ensitrelvir + Finerenone Contraindicated
- Finerenone + Itraconazole Contraindicated
- Finerenone + Ketoconazole Contraindicated
- Finerenone + Posaconazole Contraindicated
Frequently asked questions
Can I take Finerenone with Liposomal doxorubicin?
MediHelp rates the interaction as minor. Finerenone and Liposomal doxorubicin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Doxorubicin is not an established CYP3A4 inhibitor, so a meaningful rise in finerenone exposure is unlikely. Finerenone can raise serum potassium, and patients receiving chemotherapy may have vomiting, dehydration or renal impairment that increase the risk of hyperkalemia.
How serious is the interaction between Finerenone and Liposomal doxorubicin?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor serum potassium and renal function during chemotherapy cycles. Adjust the finerenone dose if potassium rises.
What other medicines interact with Liposomal doxorubicin?
MediHelp also lists interactions of Liposomal doxorubicin with, for example, Dengue vaccine, Belatacept, Cyclosporine. The full list is on the Liposomal doxorubicin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
